Semaglutide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Semaglutide and local guidelines before prescribing.
Mechanism
GLP-1 receptor agonist slowing gastric emptying and reducing appetite.
Uses
Type 2 diabetes, obesity, cardiovascular risk reduction.
Dosing
- Established atherosclerotic cardiovascular disease: Triple therapy - metformin MR, an SGLT2 inhibitor and subcutaneous semaglutide - added in sequence, titrating semaglutide to 1 mg weekly.
Endocrinology: Diabetes - Semaglutide SC weekly: 0.25 mg, then 0.5 mg, up to 1 mg for type 2 diabetes.
Endocrinology: Diabetes - Semaglutide 2.4 mg Obesity | Weekly SC, titrated over 16 weeks. NICE TA875; specialist service; maximum 2 years.
Endocrinology: Lipids and obesity
Side effects
Nausea, vomiting, diarrhoea, pancreatitis, gallstones, retinopathy complications.
Interactions
Slows absorption of oral drugs; insulin and sulfonylureas increase hypoglycaemia.
Contraindications and cautions
Pancreatitis history, medullary thyroid cancer history
Monitoring
HbA1c, weight, eyes
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive; antiemetics
Special advice
Titrate slowly; stop in suspected pancreatitis; avoid in pregnancy; monitor retinopathy.
More from the textbook: uses, cautions and other points
- GLP-1 - from the small bowel after eating; boosts insulin, reduces glucagon, slows stomach emptying and reduces appetite - the basis of semaglutide and tirzepatide for weight loss.
Endocrine: Anatomy Physiology and Pharmacology - Uses - type 2 diabetes (especially with obesity or cardiovascular disease - reduce cardiovascular events); weight management (semaglutide, liraglutide - NICE TAs, specialist weight services).
Endocrine: Anatomy Physiology and Pharmacology - Oral semaglutide : Daily; dose depends on the formulation.
Endocrinology: Diabetes - Semaglutide, liraglutide and dulaglutide reduce cardiovascular events in people with cardiovascular disease.
Endocrinology: Diabetes - Worsening of diabetic retinopathy with rapid glucose lowering (semaglutide).
Endocrinology: Lipids and obesity - Use effective contraception; stop semaglutide at least 2 months before trying to conceive.
Endocrinology: Lipids and obesity
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (4 mentions)
- Endocrinology: Diabetes (10 mentions)
- Endocrinology: Lipids and obesity (4 mentions)
- Gastroenterology: Anatomy Physiology Pharmacology (1 mention)
- Gastroenterology: Liver disease (3 mentions)
- Neurology: Anatomy, Physiology and Pharmacology (1 mention)
- Renal: Chronic Kidney Disease (1 mention)
- Renal: Glomerular Disease (1 mention)
- Ophthalmology: Retinal Visual Loss (1 mention)
- Ophthalmology: Neuro-ophthalmology (1 mention)
- Public Health: Prevention, health promotion and behaviour change (1 mention)
- Pathology: Immunopathology, amyloidosis, genetic and environmental disease (1 mention)